Who Paid My Doc
Joseph Zibrak
Pulmonary Disease Boston, MA Medical Doctor
NPI 1689655714 CMS profile 121084
330 Brookline Ave, Beth Israel Deaconess Medical Center, Boston, MA 02215
General payments
$76,148
Research payments
$15,515
Ownership & investment interest
$0
Research they led as principal investigator
$101,213
Through program year 2023, Joseph Zibrak of Boston, MA is reported in the CMS Open Payments database as having received $76,148 across 87 general payments and $15,515 in research payments paid to them. Separately, studies naming them as principal investigator received $101,213 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $3,967 | 10 | |
| 2022 | General | $10,824 | 12 | |
| 2021 | General | $4,635 | 8 | |
| 2020 | General | $7,520 | 5 | |
| 2020 | Research | $15,515 | 4 | |
| 2019 | General | $49,202 | 52 |
Beside peers
- Joseph Zibrak
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Joseph Zibrak were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Joseph Zibrak | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $49,202 | $377 | $109–$1,340 | $163 |
| 2020 | $7,520 | $230 | $56–$907 | $114 |
| 2021 | $4,635 | $269 | $68–$1,072 | $132 |
| 2022 | $10,824 | $390 | $100–$1,457 | $149 |
| 2023 | $3,967 | $419 | $114–$1,659 | $160 |
| 2024 | $0 | $476 | $123–$1,818 | $164 |
| 2025 | $0 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
240
Drug cost
$410,270
Branded share of claims
62.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ofev Nintedanib Esylate | Brand | 22 | $283,401 | |
| Pirfenidone | Generic | 15 | $65,531 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 20 | $19,056 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 21 | $13,556 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 11 | $6,757 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 18 | $6,743 | |
| Bevespi Aerosphere Glycopyrrolate/Formoterol Fum | Brand | 11 | $5,925 | |
| Serevent Diskus Salmeterol Xinafoate | Brand | 13 | $5,277 | |
| Advair Diskus Fluticasone Propion/Salmeterol | Brand | 12 | $2,225 | |
| Montelukast Sodium | Generic | 40 | $753 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
91 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Massachusetts
Related records
Pulmonary Disease in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.